INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 186 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $32,000 | – | 380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |